RMS Medical Products Announces Appointment of President and Chief Commercial Officer Donald Pettigrew

CHESTER, N.Y., Sept. 4, 2018 /PRNewswire/ — Repro Med Systems, Inc. dba RMS Medical Products (OTCQX: REPR) today announced that Donald B. Pettigrew has been appointed to the position of President and Chief Commercial Officer.

Mr. Pettigrew comes to RMS following a 23-year career in the medical device industry, where he has vast experience and demonstrated success in the home infusion space. He has held senior leadership positions at market leading medical firms such as Moog, Inc., Baxter (formerly Gambro) and Boston Scientific. At Moog, he led commercialization and business development for the IV infusion and enteral feeding franchises in both the US and OUS markets. Revenue grew $37 million over the last 3 years under his leadership, with annual revenues trending above $125 million. Mr. Pettigrew has extensive knowledge and experience in the home infusion market where he has a strong track record of driving growth and profitability by executing on commercialization strategies. He is a well-rounded executive that has worked across all customer facing and operational functions including sales, business development, manufacturing, supply chain, and product development.

 

“After a very thorough search process and being referred to us by one of our largest customers we are thrilled that Don has joined our team here at RMS,” said Dan Goldberger, Chairman and interim Chief Executive Officer. “We believe Don’s significant management experience across the entire commercialization process from product inception to patient use in the home infusion arena and his longstanding professional relationships will be invaluable to the future of our company as we work to grow the business and better serve the needs of our customers.”

 

“RMS and its Freedom infusion system have become household names among patients and customers who depend on its reliable, user- friendly and highly effective technology platform for subcutaneous and IV infusions,” said Mr. Pettigrew. “RMS is committed to developing innovative technology that empowers patients,” he added. “My priorities as President and Chief Commercial Officer are to leverage the talents of RMS’ staff and technology to grow this business and improve patient outcomes. I look forward to this tremendous opportunity to lead RMS into this next stage of the Company’s history,” said Mr. Pettigrew.

 

Prior to joining RMS, Mr. Pettigrew held senior roles at Moog, Inc. from 2011 to 2018 as Group Director, Global Business Development and Group Director, Global Sales and Professional Services.  He was Vice President of Sales at Baxter (formerly Gambro Renal Products) from 2008 to 2011 and held various sales management positions at Boston Scientific from 1995 to 2008. Mr. Pettigrew earned a BA in Biology from the University of Colorado, Boulder in 1990.

 

Forward-Looking Statements

The statements contained herein may include prospects, statements of future expectations and other forward-looking statements that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties, identified by words such as “believe”. Actual results, performance or events may differ materially from those expressed or implied in such forward-looking statements.

 

About RMS Medical Products

The Company develops, manufactures and commercializes medical products used for home infusions and suctioning. The FREEDOM Syringe Infusion System currently includes the FREEDOM60® and FreedomEdge® Syringe Infusion Drivers, RMS Precision Flow Rate Tubing™ and RMS HIgH­Flo Subcutaneous Safety Needle Sets™. These devices are used for infusions administered in professional healthcare settings as well as at home. The Company’s RES­Q­VAC® line of medical suctioning products is used by emergency medical service providers in addition to a variety of other healthcare providers. For more information about RMS Medical Products, please visit www.rmsmedicalproducts.com.

 

Contact

CG Capital 877.889.1972

investorrelations@cg.capital www.cg.capital


PDF Version